In 2020, a study demonstrated that didymin markedly alleviated hepatic steatosis and hepatocyte injury induced by dexamethasone /HFD, primarily through suppression of the TLR4/NF-κB and PI3K/AKT signaling pathways. Here, AKT1 is linked to fatty liver disease.